SLC5A2 and atherosclerosis: In patients with ASCVD, 106 (82.2%) reported initiating empagliflozin as first-line therapy alongside metformin, consistent with the 2025 ADA Standards of Care, which recommend SGLT2 inhibitors with proven cardiovascular benefit irrespective of glycemic control [12].